Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced positive topline results from the US Phase 3 ConfIdeS trial of imlifidase, evaluating 12-month kidney function ...
Sequana Medical announces H1 2025 results and provides business update alfapump® US commercialisation underway; Strengthened US reimbursement with CMS approval of NTAP "top-up" reimbursement; On track ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback